ImmuneAGE Bio

ImmuneAGE Bio

Basel, Switzerland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

ImmuneAGE Bio is an early-stage biotech venture targeting the burgeoning field of immune senescence. The company aims to translate research on how the aging immune system drives chronic disease into therapeutic interventions. Based in the life sciences hub of Basel, Switzerland, it leverages a dual approach of small molecules and advanced therapies. As a private, pre-clinical entity, its success hinges on validating its platform and advancing its first programs into the clinic.

ImmunosenescenceAge-related Diseases

Technology Platform

Proprietary platform targeting pathways of immune aging for drug discovery in small molecules and cell & gene therapies.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The company operates in the high-growth, nascent field of longevity and aging biology, targeting the fundamental driver of many chronic diseases.
A successful platform could yield therapies with multi-indication potential across oncology, infectious disease, and inflammation, representing a blockbuster opportunity.
Strategic location in Basel offers access to talent, capital, and potential pharma partners.

Risk Factors

High scientific risk in translating complex immune aging biology into safe, effective drugs.
Unproven technology platform and lack of a disclosed pipeline.
Regulatory pathway for 'aging' as an indication is undefined, requiring focus on specific diseases with associated clinical trial risks and costs.

Competitive Landscape

Competition is intensifying from both well-funded longevity biotech startups (e.g., Unity Biotechnology, Altos Labs, Calico) and large pharmaceutical companies investing in aging research. ImmuneAGE Bio must differentiate through a unique mechanistic approach or superior platform validation in the crowded immunology space.